Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Grows By 86.6%

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 348,200 shares, an increase of 86.6% from the February 13th total of 186,600 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average daily volume of 10,510,000 shares, the short-interest ratio is currently 0.0 days.

Eterna Therapeutics Stock Performance

ERNA opened at $0.26 on Friday. Eterna Therapeutics has a one year low of $0.22 and a one year high of $2.63. The company has a market cap of $1.39 million, a P/E ratio of -0.03 and a beta of 4.47. The business’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $0.70.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Eterna Therapeutics stock. Geode Capital Management LLC boosted its holdings in shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 257,310 shares of the company’s stock after purchasing an additional 236,875 shares during the period. Geode Capital Management LLC owned approximately 4.76% of Eterna Therapeutics worth $76,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.